Opioid treatment patterns, trajectories, and deprescribing indicators among hospitalised adults in Switzerland, 2020–2024: a multicentre observational cohort study

Background Despite limited evidence for non-cancer pain, opioid use has increased substantially in Europe. We aimed to characterize patterns and treatment trajectories of inpatient opioid use and to identify clinically distinct patient subgroups of heightened risk for opioid-related harm using predefined deprescribing indicators to inform hospital-based stewardship interventions. Methods This five-year, multicenter, longitudinal, observational cohort study across three Swiss tertiary referral centers (2020–2024) included adult inpatient cases with at least one systemic opioid administration during the index hospitalization using linked electronic health record data. Daily morphine milligram equivalents (MMEs) were calculated from medication administration records. Sustained therapy was defined as ≥3 consecutive treatment days. Deprescribing indicators included high-dose therapy (>90 MMEs on the final hospital day), high-risk comorbidities, and concurrent use of central nervous system depressants. Non-cancer opioid treatment trajectories were clustered using k-means analysis. Findings Among 68,129 opioid-treated cases, 78.6% (n = 53,558) had no documented cancer diagnosis. Approximately half received sustained therapy. Collectively, 11.4% (n = 7791) of 68,129 cases met at least one predefined deprescribing indicator. Musculoskeletal disorders and injury-related conditions were the primary admission diagnoses (22.9% [n = 15,575] of 68,129 cases). Opioid treatment trajectory analysis identified three distinct MME patterns among non-cancer cases, including a stable-dose subgroup (36% [n = 19,292] of 53,558) characterized by sustained therapy (89.3% [n = 17,235] of 19,292 cases), higher comorbidity burden, and greater prevalence of deprescribing indicators (33.4% [n = 17,235] of 19,292 cases). Annually, over 1200 cases were eligible for deprescribing, predominantly older adults with musculoskeletal conditions. Interpretation Inpatient opioid exposure was overall more common in non-cancer cases and often characterized by sustained therapy with only marginal dose reductions prior to discharge. Hospitals therefore represent critical intervention points for structured deprescribing approaches to prevent transitions to potentially harmful, persistent opioid use. Funding This research did not receive external funding.

Authors

Institutions

Publication Details

Journal
The Lancet Regional Health - Europe
Published
2026-11-06
DOI
https://doi.org/10.1016/j.lanepe.2026.101905
Primary Topic
Opioid Use Disorder Treatment
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Opioid treatment patterns, trajectories, and deprescribing indicators among hospitalised adults in Switzerland, 2020–2024: a multicentre observational cohort study

Roberta Noseda, Lucia Gasparovic, Balthasar L. Hug, Alessandro Ceschi et al.
1 links
The Lancet Regional Health - Europe
Opioid Use Disorder Treatment
article

Opioid treatment patterns, trajectories, and deprescribing indicators among hospitalised adults in Switzerland, 2020–2024: a multicentre observational cohort study

Roberta Noseda, Lucia Gasparovic, Balthasar L. Hug, Alessandro Ceschi, Andrea Michelle Burden, Amos Colombo, Marcel Rainer
article en

Abstract

Background Despite limited evidence for non-cancer pain, opioid use has increased substantially in Europe. We aimed to characterize patterns and treatment trajectories of inpatient opioid use and to identify clinically distinct patient subgroups of heightened risk for opioid-related harm using predefined deprescribing indicators to inform hospital-based stewardship interventions. Methods This five-year, multicenter, longitudinal, observational cohort study across three Swiss tertiary referral centers (2020–2024) included adult inpatient cases with at least one systemic opioid administration during the index hospitalization using linked electronic health record data. Daily morphine milligram equivalents (MMEs) were calculated from medication administration records. Sustained therapy was defined as ≥3 consecutive treatment days. Deprescribing indicators included high-dose therapy (>90 MMEs on the final hospital day), high-risk comorbidities, and concurrent use of central nervous system depressants. Non-cancer opioid treatment trajectories were clustered using k-means analysis. Findings Among 68,129 opioid-treated cases, 78.6% (n = 53,558) had no documented cancer diagnosis. Approximately half received sustained therapy. Collectively, 11.4% (n = 7791) of 68,129 cases met at least one predefined deprescribing indicator. Musculoskeletal disorders and injury-related conditions were the primary admission diagnoses (22.9% [n = 15,575] of 68,129 cases). Opioid treatment trajectory analysis identified three distinct MME patterns among non-cancer cases, including a stable-dose subgroup (36% [n = 19,292] of 53,558) characterized by sustained therapy (89.3% [n = 17,235] of 19,292 cases), higher comorbidity burden, and greater prevalence of deprescribing indicators (33.4% [n = 17,235] of 19,292 cases). Annually, over 1200 cases were eligible for deprescribing, predominantly older adults with musculoskeletal conditions. Interpretation Inpatient opioid exposure was overall more common in non-cancer cases and often characterized by sustained therapy with only marginal dose reductions prior to discharge. Hospitals therefore represent critical intervention points for structured deprescribing approaches to prevent transitions to potentially harmful, persistent opioid use. Funding This research did not receive external funding.

The Lancet Regional Health - EuropeVol. 72
University of Lucerne (CH), University of Alabama at Birmingham (US), ETH Zurich (CH), Ente Ospedaliero Cantonale (CH), Luzerner Kantonsspital (CH), Kantonsspital Baden (CH), Institute of Pharmaceutical Sciences (CH), Università della Svizzera italiana (CH)
Good health and well-being
Openalex Percentile: Top 12%
Opioid Use Disorder Treatment
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon